CME vs DBOEY: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
CME is the larger of the two ($111.76B market cap): the incumbent the market prices for continued execution (23.56x forward earnings, beta 0.18). DBOEY is the smaller challenger ($61.60B), priced similarly on forward earnings (22.71x): more room to run, but more to prove. If the story you believe is CME's (Record trading volumes), CME is the more direct way to own it; if it is DBOEY's (Derivatives and OTC clearing volumes), DBOEY is.
CME vs DBOEY: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | CME | DBOEY | What it tells you |
|---|---|---|---|
| Market cap | $111.76B | $61.60B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 23.56 | 22.71 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 25.59 | 24.52 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.18 | 0.27 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 85% of range | 83% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 4.20 | 5.04 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how CME and DBOEY affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CME and DBOEY share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CME and DBOEY exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does CME Group (CME) do?
CME Group operates the largest futures and options marketplace in the world, spanning six asset classes: interest rates, equity indexes, energy, agricultural commodities, metals and foreign exchange. It earns money mainly from clearing and transaction fees charged on every contract traded and cleared, plus market-data and information-services revenue, and it benefits from owning both the exchange and the clearinghouse that guarantees trades. Volumes rise with hedging demand and market volatility, which is why record average daily volume has been the main engine of recent results.
What does Deutsche Börse (DBOEY) do?
Deutsche Börse AG runs much of the plumbing of European capital markets. Its Trading and Clearing segment includes Eurex (one of the world's largest derivatives exchanges and a major euro interest-rate swap clearer), EEX for power and gas, Xetra and the Frankfurt Stock Exchange for cash equities, and 360T for foreign exchange. Clearstream holds close to EUR 18 trillion of securities in custody and runs a fund services platform. The Investment Management Solutions segment combines SimCorp, the Danish front-to-back portfolio management software firm bought in 2023, with ISS STOXX (index licensing, proxy advice and ESG data). DBOEY trades in US dollars over the counter, while the company reports in euros and its primary listing is DB1 on Xetra.
CME vs DBOEY: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- CME drivers: Record trading volumes; Interest-rate and volatility franchise.
- DBOEY drivers: Derivatives and OTC clearing volumes; SimCorp and recurring software revenue.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Revenue is cyclical and tied to trading volumes, so a prolonged low-volatility environment can depress activity and fees. For DBOEY, the 2026 results lean on unusually active markets.
CME or DBOEY: which should you pick?
With growth, valuation and volatility this close (or not yet reported for one side), the drivers above are what separate CME from DBOEY. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CME and DBOEY guides.
CME vs DBOEY: the full fundamentals
CME. CME has kept rerating upward, gaining ~12.6% in three months to ~$312 in November 2026, close to its 52-week high of ~$329, so the trailing P/E has moved to about 26 as third-quarter revenue growth returned to ~13%. Analysts' mean target of ~$318 sits just above the share price, with a buy consensus across sixteen analysts. The regular dividend alone yields ~1.7%; the variable year-end dividend, declared each December, adds to that and makes the headline blended yield materially higher.
DBOEY. Deutsche Börse trades at a premium to most European financials and close to the multiples of US exchange peers such as CME and ICE, a valuation built on recurring revenue from clearing, custody and SimCorp software plus 2026 earnings growth in the mid-teens. Trailing cash EPS is roughly EUR 12.8, so the ~EUR 327 Xetra price of mid-November works out to about 25x; Yahoo's ADR figures give ~24.5x trailing and ~22.7x forward. Figures are reported in euros and dollar values use ~1.11 USD per EUR. Ten DBOEY ADRs represent one ordinary share, so the ADR price is about one tenth of the Xetra price converted to dollars and moves with both the share price and the exchange rate.
Headline figures (approximate, November 2026): CME shows revenue (ttm) ~$6.96B (FY2025 ~$6.52B); Q3 2026 ~$1.74B, +~13% y/y, net income (ttm) ~$4.40B, profit margin ~63%, operating margin ~66%, eps (ttm / 2026 / 2027 est.) ~$12.20 trailing; ~$12.40 consensus for 2026; ~$13.25 for 2027; DBOEY shows net revenue (fy2025) ~EUR 6.0B total; ~EUR 5.2B ex treasury (+9%), net revenue ex treasury (q3 2026) ~EUR 1.42B (+14%); 9M ~EUR 4.9B (+12%), ebitda (q3 2026) ~EUR 978M total (+16%); ~EUR 760M ex treasury (+19%), cash eps ~EUR 3.28 in Q3 2026; ~EUR 10 for 9M (+14%); FY2025 EUR 11.65.
The bottom line: CME vs DBOEY
CME and DBOEY are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined CME and DBOEY exposure against your real portfolio. It is not an investment adviser.
Wondering how CME or DBOEY fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about CME Group
Ask Walnut's AI anything about CME and see how it fits what you own.
FAQ
What is the difference between CME and DBOEY?
+
CME Group operates the largest futures and options marketplace in the world, spanning six asset classes: interest rates, equity indexes, energy, agricultural commodities, metals and foreign exchange. Deutsche Börse AG runs much of the plumbing of European capital markets. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is CME or DBOEY the better stock?
+
Neither is universally better. CME is the larger incumbent; DBOEY is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, CME or DBOEY?
+
On forward P/E (as of November 2026), CME trades at 23.56x and DBOEY at 22.71x, so DBOEY is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both CME and DBOEY?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of CME vs DBOEY?
+
CME: Revenue is cyclical and tied to trading volumes, so a prolonged low-volatility environment can depress activity and fees. Competition is intensifying: FMX targets U.S. Treasury and SOFR futures with LCH clearing, ICE dominates Brent energy, and Cboe leans on VIX and options flow. A newer threat is regulated perpetual futures from crypto venues such as Coinbase and Kalshi, which the market fears could eventually breach the regulatory moat protecting high-margin retail products like 0DTE options. The stock also trades at a premium exchange multiple, so any volume slowdown or fee compression can weigh on the shares. Growth slowed sharply in the second quarter of 2026, with revenue up less than 1% year over year, before recovering to ~13% in the third. Consensus calls for ~11% EPS growth in 2026 and ~7% in 2027, which leaves a ~24x forward multiple with limited room for a volume slump. Chairman and CEO Terry Duffy sold 27,000 directly held shares (about $8.4 million) on 18 November 2026 near a record price, cutting his direct stake by about 43% to 35,442 shares, a sale the market will read alongside the stock's run. DBOEY: The 2026 results lean on unusually active markets. Rate uncertainty, tariff headlines and energy price swings drove record fixed-income and power derivatives volumes, and a calmer 2027 would slow Trading and Clearing revenue, which carries high operating leverage in both directions. The treasury result depends on euro interest rates and customer cash balances, so further ECB cuts could reverse its recent recovery. ISS STOXX faces a difficult backdrop: management called the ISS proxy and ESG business challenging, it took an ~EUR 18 million write-down on its Clarity AI stake, and US political and regulatory pressure on proxy advisers and ESG ratings could weigh on that unit, while General Atlantic's minority stake in ISS STOXX leaves a future transaction open. Allfunds brings execution risk: an in-depth EU review would delay closing, remedies could reduce the benefits, and new shares will be issued to Allfunds holders. SimCorp competes with larger, well-funded rivals. For DBOEY holders, the dollar price moves with EUR/USD, OTC liquidity is thinner than on Xetra, and German dividend withholding tax of about 26% applies unless part is reclaimed under the US treaty. Analyst caution has started to build: in November 2026 UBS called the shares overvalued after their rally and Barclays turned cautious while backing Euronext. At ~24.5x trailing earnings, a growth slowdown would likely show up in the multiple.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell CME or DBOEY; figures are approximate and dated (as of November 2026). Verify current data before investing.